Facile Expression and Purification of USP17 for use in Cancer Drug Discovery
Researchers from Purdue University have developed a methodology for the expression and purification of recombinant USP17, which allows for the utilization of a much wider array of techniques compared to cell based assays. Recombinant USP17 can be used for kinetic, structural, biochemical studies, and other studies of the enzyme and its response to drug candidates. The Purdue researchers' protocol and the resulting recombinant protein provide others with the tools to develop therapeutics against cancers in which USP17 regulation is a major component. This method will help advance the development of anticancer therapeutics that target USP17.
Recombinant protein now available Facilitates drug discovery
Drug Discovery Pharmaceutical industry Biomedical industry Biomedical and Pharmaceutical R&D Medical diagnosis
Andrew MesecarPurdue Biological SciencesAndrew MesecarPurdue Chemistry
United States
None
美国
